In April 2022, HOPA submitted a proposal to the Board of Pharmacy Specialties to continue to provide professional development programs for the recertification of board-certified pharmacists. With BPS's approval, HOPA is proud to provide Board Certified Oncology Pharmacy (BCOP) continuing education for another seven years. The new contract begins January 1, 2024 and runs through December 31, 2030.

Read the announcement: BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

HOPA Provides at Least 60 BCOP CEs Each Year

Each year, HOPA provides at least 60 BCOP Continuing Education Credits for members and other board certified hematology/oncology pharmacists. Explore the latest BCOP Updates and BCOP Self-Study Releases and more!

Tools and Resources Late Breaking News

Related Articles

Read all latest news Right Pointing Arrow
An image of acute lymphoblastic leukemia cells
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Obecabtagene autoleucel

December 16, 2025

Crystal Chung, PharmD, PGY2 Oncology Pharmacy Resident, and Emma Sheldon, PharmD, BCOP, Oncology Pharmacy Specialist - Bone Marrow Transplant/Cellular Therapy, both from Scripps Health in San Diego, CA, discuss obecabtagene autoleucel (Aucatzyl).

An image of a brain x-ray
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Dordaviprone

December 15, 2025

Nghi Nguyen, PharmD, PGY1 Pharmacy Resident, and Andrea Clarke, PharmD, BCOP, Hematology/Cellular Therapy Clinical Pharmacy Specialist - both from Wellstar MCG Health in Augusta, GA - deep dive into the potential role and clinical pearls of dordaviprone.

An image of multiple myeloma cells
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Linvoseltamab-gcpt

December 04, 2025

Nikki Kalem, PharmD, PGY2 Oncology Pharmacy Resident, at Henry Ford Hospital in Detroit, MI, writes about the recent accelerated approval of linvoseltamab-gcpt for the treatment of relapsed or refractory multiple myeloma in adults.